Sequence-specific pharmacokinetic and pharmacodynamic phase I/Ib study of olaparib tablets and carboplatin in women’s cancer

PURPOSE: Our preclinical studies showed that the PARP inhibitor, olaparib prior to carboplatin attenuated carboplatin cytotoxicity. We evaluated sequence-specific pharmacokinetic and pharmacodynamic (PK/PD) effects, safety and activity of the combination. PATIENTS AND METHODS: Eligible patients had...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Lee, Jung-Min, Peer, Cody J., Yu, Minshu, Amable, Lauren, Gordon, Nicolas, Annunziata, Christina M., Houston, Nicole, Goey, Andrew K.L., Sissung, Tristan M., Parker, Bernard, Minasian, Lori, Chiou, Victoria L., Murphy, Robert, Widemann, Brigitte, Figg, William D., Kohn, Elise C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5354956/
https://ncbi.nlm.nih.gov/pubmed/27663600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1546
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados